FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2395504349> ?p ?o ?g. }

• W2395504349 endingPage "1006" @default.
• W2395504349 startingPage "1001" @default.
• W2395504349 abstract "No AccessJournal of Urology1 May 1983Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer S.A. Loening, S. Beckle, M.F. Brady, T.M. Chu, J.B. Dekernion, C. Dhabuwala, J.F. Gaeta, R.P. Gibbons, C.F. Mckiel, D.G. McLeod, J.E. Pontes, G.R. Prout, P.T. Scardino, J.U. Schlegel, J.D. Schmidt, W.W. Scott, N.H. Slack, M.S. Soloway, and G.P. Murphy S.A. LoeningS.A. Loening More articles by this author , S. BeckleS. Beckle More articles by this author , M.F. BradyM.F. Brady More articles by this author , T.M. ChuT.M. Chu More articles by this author , J.B. DekernionJ.B. Dekernion More articles by this author , C. DhabuwalaC. Dhabuwala More articles by this author , J.F. GaetaJ.F. Gaeta More articles by this author , R.P. GibbonsR.P. Gibbons More articles by this author , C.F. MckielC.F. Mckiel More articles by this author , D.G. McLeodD.G. McLeod More articles by this author , J.E. PontesJ.E. Pontes More articles by this author , G.R. ProutG.R. Prout More articles by this author , P.T. ScardinoP.T. Scardino More articles by this author , J.U. SchlegelJ.U. Schlegel More articles by this author , J.D. SchmidtJ.D. Schmidt More articles by this author , W.W. ScottW.W. Scott More articles by this author , N.H. SlackN.H. Slack More articles by this author , M.S. SolowayM.S. Soloway More articles by this author , and G.P. MurphyG.P. Murphy More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)52509-4AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail In this clinical trial of men with advanced prostatic cancer no longer responsive to hormonetherapy 189 were randomized to receive estramustine phosphate, methotrexate or cis-platinum. Response evaluations were done in 158 cases. Objective response rates (complete, partial or stabilization of disease) were 34 per cent for estramustine phosphate, 36 per cent for cis-platinum and 41 per cent for methotrexate. Subjective parameters indicated a substantial advantage for pain improvement with methotrexate or cis-platinum over estramustine phosphate. P:robabilities of continued response indicated some advantage for methotrexate and median response durations at this time were twice as long for methot:rexate 32 weeks) as for cis-platinum (16 weeks), with estramustine phosphate intermediate (23 weeks). Survival rates for the original treatment randomization groups were not different at this time. Side effects of estramustine phosphate consisted primarily of nausea and vomiting and/or anorexia but to a lesser extent than with cis-platinum. These effects were somewhat less for methotrexate, for which the major side effects were stomatitis and leukopenia, as well as hepatic toxicity reflected by elevated serum glutamic oxaloacetic transaminase levels. Other side effects of cis-platinum were less than for methotrexate (no stomatitis), except for signs of renal toxicity (elevations in blood urea nitrogen and serum creatinine), which were greater. Methotrexate had a relatively high level of activity against metastatic, progressive, hormone non:responsive prostatic cancer, with side effects that were substantial but manageable. © 1983 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByTaneja S (2016) Re: DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJournal of Urology, VOL. 195, NO. 4 Part 1, (925-928), Online publication date: 1-Apr-2016.Daliani D, Eisenberg P, Weems J, Lord R, Fueger R and Logothetis C (2018) The Results of a Phase II Randomized Trial Comparing 5-Fluorouracil and 5-Fluorouracil Plus alpha-Interferon: Observations on the Design of Clinical Trials for Androgen-Independent Prostate CancerJournal of Urology, VOL. 153, NO. 5, (1587-1591), Online publication date: 1-May-1995. Volume 129Issue 5May 1983Page: 1001-1006 Advertisement Copyright & Permissions© 1983 by The American Urological Association Education and Research, Inc.MetricsAuthor Information S.A. Loening More articles by this author S. Beckle More articles by this author M.F. Brady More articles by this author T.M. Chu More articles by this author J.B. Dekernion More articles by this author C. Dhabuwala More articles by this author J.F. Gaeta More articles by this author R.P. Gibbons More articles by this author C.F. Mckiel More articles by this author D.G. McLeod More articles by this author J.E. Pontes More articles by this author G.R. Prout More articles by this author P.T. Scardino More articles by this author J.U. Schlegel More articles by this author J.D. Schmidt More articles by this author W.W. Scott More articles by this author N.H. Slack More articles by this author M.S. Soloway More articles by this author G.P. Murphy More articles by this author Expand All Advertisement PDF DownloadLoading ..." @default.
• W2395504349 created "2016-06-24" @default.
• W2395504349 creator A5009695382 @default.
• W2395504349 creator A5014456130 @default.
• W2395504349 creator A5014715397 @default.
• W2395504349 creator A5014935051 @default.
• W2395504349 creator A5025985212 @default.
• W2395504349 creator A5026841294 @default.
• W2395504349 creator A5035279287 @default.
• W2395504349 creator A5044222070 @default.
• W2395504349 creator A5045466774 @default.
• W2395504349 creator A5046567477 @default.
• W2395504349 creator A5047560942 @default.
• W2395504349 creator A5047566332 @default.
• W2395504349 creator A5047748639 @default.
• W2395504349 creator A5052554861 @default.
• W2395504349 creator A5057788980 @default.
• W2395504349 creator A5063378114 @default.
• W2395504349 creator A5063968899 @default.
• W2395504349 creator A5087322472 @default.
• W2395504349 creator A5088713549 @default.
• W2395504349 date "1983-05-01" @default.
• W2395504349 modified "2023-09-27" @default.
• W2395504349 title "Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer" @default.
• W2395504349 cites W154227715 @default.
• W2395504349 cites W1974031166 @default.
• W2395504349 cites W1976734173 @default.
• W2395504349 cites W1977543620 @default.
• W2395504349 cites W2007225257 @default.
• W2395504349 cites W2011045319 @default.
• W2395504349 cites W2053188628 @default.
• W2395504349 cites W2106147539 @default.
• W2395504349 cites W2187668060 @default.
• W2395504349 cites W2317833459 @default.
• W2395504349 cites W2396172779 @default.
• W2395504349 cites W2399812236 @default.
• W2395504349 cites W2403575589 @default.
• W2395504349 cites W2406607853 @default.
• W2395504349 cites W2415300933 @default.
• W2395504349 cites W2415904659 @default.
• W2395504349 cites W2468876703 @default.
• W2395504349 doi "https://doi.org/10.1016/s0022-5347(17)52509-4" @default.
• W2395504349 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6343629" @default.
• W2395504349 hasPublicationYear "1983" @default.
• W2395504349 type Work @default.
• W2395504349 sameAs 2395504349 @default.
• W2395504349 citedByCount "80" @default.
• W2395504349 countsByYear W23955043492013 @default.
• W2395504349 countsByYear W23955043492016 @default.
• W2395504349 countsByYear W23955043492017 @default.
• W2395504349 countsByYear W23955043492018 @default.
• W2395504349 countsByYear W23955043492020 @default.
• W2395504349 crossrefType "journal-article" @default.
• W2395504349 hasAuthorship W2395504349A5009695382 @default.
• W2395504349 hasAuthorship W2395504349A5014456130 @default.
• W2395504349 hasAuthorship W2395504349A5014715397 @default.
• W2395504349 hasAuthorship W2395504349A5014935051 @default.
• W2395504349 hasAuthorship W2395504349A5025985212 @default.
• W2395504349 hasAuthorship W2395504349A5026841294 @default.
• W2395504349 hasAuthorship W2395504349A5035279287 @default.
• W2395504349 hasAuthorship W2395504349A5044222070 @default.
• W2395504349 hasAuthorship W2395504349A5045466774 @default.
• W2395504349 hasAuthorship W2395504349A5046567477 @default.
• W2395504349 hasAuthorship W2395504349A5047560942 @default.
• W2395504349 hasAuthorship W2395504349A5047566332 @default.
• W2395504349 hasAuthorship W2395504349A5047748639 @default.
• W2395504349 hasAuthorship W2395504349A5052554861 @default.
• W2395504349 hasAuthorship W2395504349A5057788980 @default.
• W2395504349 hasAuthorship W2395504349A5063378114 @default.
• W2395504349 hasAuthorship W2395504349A5063968899 @default.
• W2395504349 hasAuthorship W2395504349A5087322472 @default.
• W2395504349 hasAuthorship W2395504349A5088713549 @default.
• W2395504349 hasConcept C121608353 @default.
• W2395504349 hasConcept C126322002 @default.
• W2395504349 hasConcept C185592680 @default.
• W2395504349 hasConcept C2780192828 @default.
• W2395504349 hasConcept C2780201970 @default.
• W2395504349 hasConcept C2994223898 @default.
• W2395504349 hasConcept C71240020 @default.
• W2395504349 hasConcept C71924100 @default.
• W2395504349 hasConceptScore W2395504349C121608353 @default.
• W2395504349 hasConceptScore W2395504349C126322002 @default.
• W2395504349 hasConceptScore W2395504349C185592680 @default.
• W2395504349 hasConceptScore W2395504349C2780192828 @default.
• W2395504349 hasConceptScore W2395504349C2780201970 @default.
• W2395504349 hasConceptScore W2395504349C2994223898 @default.
• W2395504349 hasConceptScore W2395504349C71240020 @default.
• W2395504349 hasConceptScore W2395504349C71924100 @default.
• W2395504349 hasIssue "5" @default.
• W2395504349 hasLocation W23955043491 @default.
• W2395504349 hasLocation W23955043492 @default.
• W2395504349 hasOpenAccess W2395504349 @default.
• W2395504349 hasPrimaryLocation W23955043491 @default.
• W2395504349 hasRelatedWork W2010765098 @default.
• W2395504349 hasRelatedWork W2062527958 @default.
• W2395504349 hasRelatedWork W2084713386 @default.
• W2395504349 hasRelatedWork W2155169688 @default.
• W2395504349 hasRelatedWork W2315764680 @default.

• next